Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $11 from $10.35 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened “positive catalyst watches” on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy Rating
- Tandem Diabetes upgraded to Neutral from Sell at Citi
- Tandem Diabetes Care: Upgraded to Neutral/High Risk Amid Valuation and Acquisition Interest
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
- Tandem Diabetes downgraded to Hold from Buy at Lake Street